Get started
Work

Abstract PD1-08: Trade: 6-month abemaciclib tolerability after initial dose escalation in early HR+/HER2- breast cancer

Year: 2026
Type: conference-abstract
DOI: 10.1158/1557-3265.sabcs25-pd1-08
Authors: I. Schlam, D. Trapani, S. Kim, M. Faggen, N. Sinclair, P. Sanz-Altamira, C. Battelli, S. Berwick, S. Lo, J. Acevedo, S. Sinclair, A. Malcom, L. Varella, S. L. Sammons, S. T. Schumer, P. D. Poorvu, E. P. Wallace, E. Pasternak, N. Tayob, S. M. Tolaney, E. L. Mayer
Institutions: Dana-Farber Cancer Institute, European Institute of Oncology, New England Cancer Specialists, Beth Israel Deaconess Medical Center, Stamford Hospital, Boston Medical Center
Language: English
Field: Medicine
Open Access status: closed
OpenAlex ID: W7129535428
Cites:
Cited by:
Related to: